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Summary  A  45-year-old  man  presented  with  acute  inferior  myocardial  infarction  and  under-
went  emergent  coronary  angiography  (CAG).  CAG  revealed  total  occlusion  of  both  the  proximal
right  coronary  artery  (RCA)  and  distal  left  circumﬂex  artery,  and  two  bare-metal  stents  were
deployed  in  the  RCA.  After  the  procedure,  dual  antiplatelet  therapy  (DAT)  with  100  mg  aspirin
and  75  mg  clopidogrel  daily  were  given  as  usual,  however,  stent  thrombosis  occurred  three  times
and  he  underwent  repeat  interventions.  To  investigate  the  cause  of  repeated  stent  thrombosis,
the  platelet  function  during  DAT  was  measured.  The  result  showed  that  he  did  not  achieve  an
adequate  antiplatelet  effect.
Clopidogrel is  a  prodrug  that  requires  biotransformation  by  cytochrome  P450  (CYP)  enzyme  in
the  liver.  Recently,  the  carriers  of  CYP2C19*2  or  *3  null-of-function  allele,  have  been  shown  to
demonstrate  an  increased  risk  of  cardiovascular  events,  including  stent  thrombosis,  compared
with  non-carriers.  This  patient  carried  the  CYP2C19*3/*3  genotype.
This is  the  ﬁrst  report  of  repetitive  stent  thrombosis  in  a  poor  metabolizer  carrying  two
loss-of-function  alleles  (CYP2C19*3/*3).
f  Car© 2011  Japanese  College  o∗ Corresponding author. Tel.: +81 96 373 5175;
ax: +81 96 362 3256.
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ntroductionual  antiplatelet  therapy  (DAT)  with  100  mg  aspirin  and
5 mg  clopidogrel  daily  is  the  standard  treatment  to  pre-
ent stent  thrombosis  [1],  however,  some  patients  do  not
 Published by Elsevier Ltd. All rights reserved.
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aFigure  1  (A)  Total  occlusion  of  the  proximal  right  coronary  ar
achieve  an  adequate  antiplatelet  effect  with  clopidogrel,
which may  be  associated  with  stent  thrombosis.  Because
clopidogrel is  a  prodrug  that  requires  biotransformation  to
an active  metabolite  by  cytochrome  P450  (CYP)  enzyme  in
the liver,  CYP  polymorphisms  are  reportedly  associated  with
high on-clopidogrel  platelet  reactivity.  Speciﬁcally,  carri-
ers of  the  CYP2C19*2  or  *3  allele,  with  null  functions,  have
been shown  to  demonstrate  a  higher  rate  of  cardiovascular
events, including  stent  thrombosis,  than  non-carriers  [2].
Case report
In  February  2009,  a  45-year-old  man  was  admitted  to  the
emergency department  complaining  of  sudden  left-sided
chest and  shoulder  pain  with  nausea  and  cold  sweats.
His only  cardiac  risk  factor  was  dyslipidemia.  An  elec-
trocardiogram (ECG)  showed  ST  segment  elevation  in  the
inferior leads  and  echocardiogram  revealed  reduced  wall
motion in  the  inferior  wall.  He  was  diagnosed  with  acute
inferior myocardial  infarction  and  underwent  emergent
coronary angiography  (CAG).  CAG  revealed  total  occlu-
sion of  both  the  proximal  right  coronary  artery  (RCA)  and
distal left  circumﬂex  artery  (Fig.  1A).  Two  3.0  × 18 mm
and 3.0  × 12 mm  Driver  stents  (Medtronic,  Minneapolis,  MN,
USA) were  deployed  in  the  culprit  lesion  in  the  RCA,  with
excellent results  (Fig.  1B).  Before  percutaneous  coronary
intervention (PCI),  200  mg  aspirin  and  300  mg  clopidogrel
were given  as  loading,  followed  by  100  mg  aspirin  and  75  mg
clopidogrel daily  as  maintenance  doses.  Three  days  after
ﬁrst PCI,  ECG  revealed  the  recurrence  of  ST  segment  eleva-
tion in  the  inferior  leads,  and  he  immediately  underwent
emergent CAG.  Angiography  revealed  total  occlusion  of
the proximal  RCA  due  to  early  stent  thrombosis  (Fig.  2A).
Balloon angioplasty  was  performed  several  times,  and  a
3.0 ×  24  mm  Driver  stent  was  deployed  again,  but  thrombi
immediately occurred  in  the  stents.  Finally,  intra-aortic
balloon pumping  (IABP)  was  employed,  and  adequate  ante-
grade coronary  ﬂow  was  achieved  after  repeated  balloon
angioplasty. Although  continuous  infusion  of  heparin  and
administration of  warfarin  were  added  after  re-PCI  to  inhibit
thrombogenesis, stent  thrombosis  recurred  5  days  after  the
second PCI  (Fig.  2B).  Thrombectomy  and  a  3.5  ×  23  mm
a
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t (arrow).  (B)  Post-stent  deployment,  with  excellent  results.
river  stent  deployment  were  performed  with  IABP.  Unfor-
unately, he  developed  chest  discomfort  with  increased
ardiac enzymes  13  days  after  the  third  PCI.  CAG  revealed
 third  stent  thrombosis  (Fig.  2C)  and  thrombectomy,  and
.5 × 33 mm  and  3.5  × 23 mm  Cypher  stents  (Cordis,  Miami
akes, FL,  USA)  were  deployed.  After  this  procedure,  DAT
ith 100  mg  aspirin  and  75  mg  clopidogrel  was  changed  to
riple antiplatelet  therapy  (TAT)  with  200  mg  aspirin,  75  mg
lopidgrel, and  200  mg  cilostazol  daily.  There  was  no  fur-
her stent  thrombosis  and  no  stent  restenosis  for  6  months
Fig. 2D).
To examine  the  cause  of  repeated  stent  thrombosis,
he platelet  function  during  DAT  was  measured  using  a
ight transmittance  aggregometer  (MCM  HEMA  TRACER  313;
AM12C; LMS  Inc.,  Japan)  with  a strong  suspicion  of  high
latelet reactivity  after  repeated  PCI.  As  a  result,  20  mol/L
denosine diphosphate-induced  platelet  aggregation  was
1% at  maximum,  and  showed  6269  aggregation  units  ×  min
rom the  area  under  the  platelet  aggregation  curve.  These
ndings revealed  the  reduced  antiplatelet  efﬁcacy  of  clopi-
ogrel. To  elucidate  the  causes  of  the  reduced  antiplatelet
fﬁcacy, we  performed  CYP2C19  genotype  analysis  around
he same  time  that  we  measured  the  platelet  function.  He
ad homogenous  variants  at  exon  4  of  CYP2C19*3/*3,  which
howed him  to  be  a  poor  metabolizer.  In  this  case,  clopido-
rel hyporesponsiveness  by  CYP2C19  polymorphisms  may  be
ne of  the  reasons  for  repeated  stent  thrombosis.
iscussion
he  causes  of  early  stent  thrombosis  are  multifactorial,
uch as  residual  target  lesion  thrombus  or  dissection,  stasis,
tent underexpansion,  unstable  hemodynamics,  dehydra-
ion, heparin-induced  thrombocytopenia  [3]  and  clopidogrel
yporesponsiveness [4].  Although  intravascular  ultrasound
IVUS) was  not  used,  there  was  no  thrombus  or  dissec-
ion and  an  adequate  vessel  diameter  was  obtained  by
ngiographic evaluation.  His  hemodynamics  were  stable
nd dehydration  did  not  occur  in  the  course  of  treat-
ent. There  was  no  decrease  in  the  number  of  platelets
nd no  evidence  of  embolism  during  the  treatment  period,
herefore, we  thought  the  possibility  of  heparin-induced
e18  S.  Takashio  et  al.
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CFigure  2  (A)—(C)  Repeated  stent  thrombosis  (arrowh
hrombocytopenia  was  very  low.  For  these  reasons,  we
hought that  high  on-clopidogrel  platelet  reactivity  played
 key  role  in  repeat  stent  thrombosis.  Similarly,  the  mech-
nisms of  a  poor  response  to  clopidogrel  are  multifactorial,
uch as  age,  renal  failure,  body  mass  index,  diabetes,  high
lasma ﬁbrinogen,  lack  of  adherence,  and  CYP  polymor-
hisms [5—7].  In  this  case,  the  level  of  plasma  ﬁbrinogen
as normal  and  the  other  factors  seemed  to  be  inappli-
able. Hence,  we  strongly  suspected  that  the  cause  of
igh on-clopidogrel  platelet  reactivity  was  CYP  polymor-
hisms.
To the  best  of  our  knowledge,  this  is  the  ﬁrst  report  of
epetitive stent  thrombosis  in  a  poor  metabolizer  carrying
wo loss-of-function  alleles  of  CYP2C19.  The  rate  of  poor
etabolizers and  CYP2C19*3/*3  carrier  is  reportedly  about
9% and  1%,  respectively,  in  Japanese  patients  with  coronary
eart disease.  We  reported  that  poor  metabolizers  show  high
n-clopidogrel platelet  reactivity  compared  with  extensive
etabolizers carrying  normal  function  alleles,  or  interme-
iate metabolizers  carrying  one  loss-of-function  allele  [8].
lthough it  was  reported  that  there  was  no  difference  in
lopidogrel reactivity  between  CYP2C19*2  and  CYP2C19*3
arriers [9],  the  functional  difference  between  *2  and  *3
s still  obscure  in  clinical  practice  such  as  the  occurrence
f cardiovascular  events,  including  stent  thrombosis.  Fur-
her studies  are  needed  to  clarify  the  meaning  of  CYP2C19*3
arrier.
I
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o (D)  No  stent  restenosis  after  repeat  PCI  for  6  months.
Cilostazol  is  a potent  oral  antiplatelet  agent  inhibitor
f type  III  phosphodiesterase,  a  mechanism  different  from
denosine diphosphate  receptor  antagonists.  It  was  reported
hat TAT  seemed  to  be  more  effective  in  preventing  throm-
otic complications  after  stenting  than  DAT  and  might  be
pplied in  patients  with  high  risk  of  stent  thrombosis  [10].
lthough the  platelet  function  was  not  measured  during
AT in  this  case,  the  platelet  function  might  be  inhibited
y the  use  of  cilostazol  via  a  different  antiplatelet  mecha-
ism.
We selected  a sirolimus-eluting  stent  at  the  last  PCI,
owever, the  use  of  drug-eluting  stent  should  have  been
voided under  the  high-risk  situation  of  stent  thrombosis  or
igh platelet  reactivity.  It  would  be  difﬁcult  to  fully  explain
he mechanism  of  the  repetition  of  stent  thrombosis  without
VUS observation  because  we  could  not  promise  the  absence
f dissection  and  stent  underexpansion.  IVUS  should  be  used
o evaluate  the  intravascular  lumen  and  stent  when  stent
hrombosis occurs.
onclusionn  this  case  report,  we  described  a  patient  with  early  stent
hrombosis with  the  CYP2C19*3/*3  genotype.  When  stent
hrombosis occurs,  evaluation  of  the  platelet  function  is  rec-
mmended if  possible,  however,  it  is  impossible  to  measure
C19*
[Repetitive  early  stent  thrombosis  in  a  patient  with  the  CYP2
platelet  reactivity  at  all  sites.  It  may  be  a  useful  procedure
to add  another  antiplatelet  agent,  for  example,  cilostazol,
to DAT  in  cases  of  suspected  high  on-treatment  platelet
reactivity.
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